We are live on ! Find out more
LBPH

Longboard Pharmaceuticals, Inc. Common Stock

Delisted

LBPH was delisted on the 29th of November, 2024.

52 hedge funds and large institutions have $99.9M invested in Longboard Pharmaceuticals, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

130% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 10

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

15% more capital invested

Capital invested by funds: $87.1M → $99.9M (+$12.8M)

2% more funds holding

Funds holding: 5152 (+1)

Holders
52
Holders Change
+1
Holders Change %
+1.96%
% of All Funds
0.76%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
23
Reduced
10
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$14.2M
Fidelity Investments
2
Fidelity Investments
Massachusetts
$9.95M -$2.31M -463,570 -22%
T. Rowe Price Associates
3
T. Rowe Price Associates
Maryland
$9.81M -$724K -145,366 -8%
FCM
4
Farallon Capital Management
California
$9.41M
PCH
5
Polar Capital Holdings
United Kingdom
$6.03M
IC
6
Ikarian Capital
Texas
$5.91M +$2.32M +465,361 +91%
IHAM
7
Integral Health Asset Management
New York
$5.43M +$698K +140,000 +18%
BlackRock
8
BlackRock
New York
$5.25M +$419K +84,043 +11%
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$4.97M
Vanguard Group
10
Vanguard Group
Pennsylvania
$4.74M +$26.7K +5,360 +0.7%
JP Morgan Chase
11
JP Morgan Chase
New York
$3.22M +$6.05K +1,214 +0.2%
Jennison Associates
12
Jennison Associates
New York
$2.9M +$2.4M +480,828 New
PHP
13
Parkman Healthcare Partners
Connecticut
$2.59M +$368K +73,935 +21%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$2.02M +$14.8K +2,972 +0.9%
Ensign Peak Advisors
15
Ensign Peak Advisors
Utah
$1.82M +$1.5M +301,161 New
State Street
16
State Street
Massachusetts
$1.8M +$22.9K +4,600 +2%
BFM
17
Boothbay Fund Management
New York
$1.4M +$592K +118,857 +106%
CIBC Asset Management
18
CIBC Asset Management
Ontario, Canada
$1.28M +$337K +67,607 +47%
Northern Trust
19
Northern Trust
Illinois
$922K +$79.3K +15,922 +12%
PIM
20
Platinum Investment Management
Australia
$766K +$633K +127,048 New
UOC
21
UBS O'Connor
Illinois
$743K -$693K -139,059 -53%
TD Asset Management
22
TD Asset Management
Ontario, Canada
$567K -$137K -27,400 -23%
SSA
23
Schonfeld Strategic Advisors
New York
$557K +$41.4K +8,300 +10%
BCM
24
Bridgeway Capital Management
Texas
$422K +$99.7K +20,000 +40%
Morgan Stanley
25
Morgan Stanley
New York
$384K +$282K +56,586 +801%

LBPH Hedge Fund Activity: Q4 2023 in Review

52 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Longboard Pharmaceuticals, Inc. Common Stock (LBPH) for Q4 2023, worth a combined $99.9M — up 15% from $87.1M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new LBPH positions and 6 closed out — a net gain of 1 holder — while 23 added to existing stakes and 10 trimmed.

The largest buyer was Jennison Associates, opening a new position worth an estimated $2.4M. The largest seller was Fidelity Investments, cutting an estimated $2.31M.

  • 52 institutional investors held Longboard Pharmaceuticals, Inc. Common Stock (LBPH) as of Q4 2023, up from 51 in Q3 2023.
  • Funds reported $99.9M of Longboard Pharmaceuticals, Inc. Common Stock stock for Q4 2023, up 15% quarter-over-quarter.
  • 7 funds opened new Longboard Pharmaceuticals, Inc. Common Stock positions in Q4 2023 and 6 closed out, a net change of +1 holder.
  • The largest Longboard Pharmaceuticals, Inc. Common Stock buyer in Q4 2023 was Jennison Associates, an estimated $2.4M added.
  • The largest Longboard Pharmaceuticals, Inc. Common Stock seller in Q4 2023 was Fidelity Investments, an estimated $2.31M sold.

Based on aggregated 13F filings for Q4 2023.